<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628056</url>
  </required_header>
  <id_info>
    <org_study_id>RRK3159</org_study_id>
    <secondary_id>PG/06/104/21466</secondary_id>
    <nct_id>NCT00628056</nct_id>
  </id_info>
  <brief_title>Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes</brief_title>
  <acronym>DDCM</acronym>
  <official_title>Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes increases the risk of heart failure. This is mainly due to a disease of the blood
      vessels supplying the heart muscle and/or high blood pressure, but abnormal metabolism may
      also contribute. We plan to study the mechanisms involved in this abnormal metabolism, whilst
      also assessing the effects of a drug called Perhexiline which improves the abnormal
      metabolism that is present in diabetic patients before the development of heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Anticipated">April 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point of the Perhexiline intervention study will be the change in cardiac PCr/ATP ratio.</measure>
    <time_frame>2 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Diabetic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perhexiline</intervention_name>
    <description>Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes Mellitus(WHO definition)

          -  HbA1C &lt;9

          -  No history of chest pain

          -  No evidence of Coronary Artery Disease or peripheral vascular disease

          -  Left ventricular ejection fraction over 50%

          -  No evidence of respiratory disease

        Exclusion Criteria:

          -  Patients &lt; 16years or who cannot provide informed consent

          -  Evidence of significant epicardial coronary artery disease

          -  Evidence of peripheral vascular disease

          -  Abnormal liver function tests

          -  Clinically apparent peripheral neuropathy

          -  Severe chronic renal failure (creatinine &gt;250) or diabetic nephropathy

          -  Concomitant use of Amiodarone, Quinidine, Haloperidol or Selective serotonin (5HT)
             uptake inhibitors such as Fluoxetine and Paroxetine which may inhibit the CYP2D6
             enzyme

          -  Patients on statin therapy for primary dyslipidemia.

          -  Patients with recurrent hypoglycaemia

          -  Women of child bearing age who are not using effective contraception (or if pregnancy
             test positive)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Frenneaux, MD FRCP FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ganesh Nallur Shivu, MBBS MRCP</last_name>
    <phone>0044 1214145916</phone>
    <email>drgani23@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Westmidlands</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Frenneaux, MD FRCP FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2008</study_first_posted>
  <last_update_submitted>February 24, 2008</last_update_submitted>
  <last_update_submitted_qc>February 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof Michael Frenneaux</name_title>
    <organization>University of Birmingham</organization>
  </responsible_party>
  <keyword>Perhexiline</keyword>
  <keyword>diabetes</keyword>
  <keyword>diabetic cardiomyopathy</keyword>
  <keyword>high energy phosphate kinetics</keyword>
  <keyword>magnetic resonance spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Diabetic Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perhexiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

